- Home
- BW vs IMMX Comparison
BW vs IMMX Comparison
Compare BW & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- IMMX
- Stock Information
- Founded
- BW 1867
- IMMX 2014
- Country
- BW United States
- IMMX United States
- Employees
- BW N/A
- IMMX N/A
- Industry
- BW Building Products
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BW Industrials
- IMMX Health Care
- Exchange
- BW Nasdaq
- IMMX Nasdaq
- Market Cap
- BW 45.3M
- IMMX 54.9M
- IPO Year
- BW N/A
- IMMX 2021
- Fundamental
- Price
- BW $0.84
- IMMX $2.04
- Analyst Decision
- BW Buy
- IMMX Strong Buy
- Analyst Count
- BW 2
- IMMX 1
- Target Price
- BW $3.50
- IMMX $7.00
- AVG Volume (30 Days)
- BW 1.8M
- IMMX 398.8K
- Earning Date
- BW 05-12-2025
- IMMX 06-10-2025
- Dividend Yield
- BW N/A
- IMMX N/A
- EPS Growth
- BW N/A
- IMMX N/A
- EPS
- BW N/A
- IMMX N/A
- Revenue
- BW $734,239,000.00
- IMMX N/A
- Revenue This Year
- BW $9.70
- IMMX N/A
- Revenue Next Year
- BW $10.16
- IMMX N/A
- P/E Ratio
- BW N/A
- IMMX N/A
- Revenue Growth
- BW 12.90
- IMMX N/A
- 52 Week Low
- BW $0.22
- IMMX $1.26
- 52 Week High
- BW $2.99
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- BW 61.11
- IMMX 65.54
- Support Level
- BW $0.68
- IMMX $1.89
- Resistance Level
- BW $0.79
- IMMX $2.50
- Average True Range (ATR)
- BW 0.10
- IMMX 0.18
- MACD
- BW 0.00
- IMMX 0.04
- Stochastic Oscillator
- BW 59.41
- IMMX 85.71
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.